📊 BHST Key Takeaways
Is Bioharvest Sciences Inc.. (BHST) a Good Investment?
BioHarvest Sciences presents substantial analytical risk due to complete absence of reportable financial data across all fundamental metrics. With zero revenue, no profitability indicators, no balance sheet data, and only 1 metric available from SEC filings, the company appears to be pre-revenue or non-operational. The lack of insider activity (0 Form 4 filings in 90 days) combined with missing financial data suggests minimal operational progress.
BioHarvest Sciences is delivering strong top-line growth and meaningful gross margin expansion, with revenue rising from $12.7M in 2023 to $25.2M in 2024 and reaching $25.4M in the first nine months of 2025 versus $17.9M a year earlier. However, the business remains fundamentally weak on self-funding metrics: it is still loss-making, generates negative operating cash flow, and the SEC filings explicitly disclose substantial doubt about its ability to continue as a going concern without additional external financing. Growth quality is improving, but financial health is still too dependent on capital raises and debt conversion to warrant a positive fundamental view.
Why Buy Bioharvest Sciences Inc.. Stock? BHST Key Strengths
- Listed on Nasdaq indicating regulatory compliance standards
- CIK registration demonstrates SEC reporting entity status
- Operating in pharmaceutical sector with potential long-term market opportunity
- Revenue growth has been strong, roughly doubling in 2024 and continuing to grow in 2025
- Gross profitability improved materially, with gross profit rising faster than revenue and operating losses narrowing year over year
- Balance sheet improved in 2025 with cash increasing and shareholders' equity turning more positive after financing actions
BHST Stock Risks: Bioharvest Sciences Inc.. Investment Risks
- Complete absence of revenue and profitability metrics
- No balance sheet data available indicating non-reporting status or financial distress
- Zero insider transactions in 90 days suggests lack of management confidence
- Pharmaceutical sector carries high R&D costs and regulatory risk
- Insufficient financial transparency for fundamental analysis
- The company remains unprofitable with persistent net losses and negative operating cash flow
- SEC filings include a going-concern warning and management states the business still depends on fundraising to finance operations
- Liquidity improvement has come largely from financing transactions, including loans, warrant exercises, and equity offerings rather than internally generated cash
Key Metrics to Watch
- Revenue generation and gross margin initiation
- Balance sheet composition and cash runway
- Insider buying activity and management confidence indicators
- SEC filing frequency and data availability improvements
- Cash burn rate and path to profitability
- Operating cash flow and free-cash-flow trajectory
- Operating margin improvement relative to revenue growth
Bioharvest Sciences Inc.. (BHST) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
BHST Profit Margin, ROE & Profitability Analysis
BHST vs Healthcare Sector: How Bioharvest Sciences Inc.. Compares
How Bioharvest Sciences Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Bioharvest Sciences Inc.. Stock Overvalued? BHST Valuation Analysis 2026
Based on fundamental analysis, Bioharvest Sciences Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Bioharvest Sciences Inc.. Balance Sheet: BHST Debt, Cash & Liquidity
BHST Revenue Growth, EPS Growth & YoY Performance
BHST SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Bioharvest Sciences Inc.. (CIK: 0001723464)
❓ Frequently Asked Questions about BHST
What is the AI rating for BHST?
Bioharvest Sciences Inc.. (BHST) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 84% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BHST's key strengths?
Claude: Listed on Nasdaq indicating regulatory compliance standards. CIK registration demonstrates SEC reporting entity status. ChatGPT: Revenue growth has been strong, roughly doubling in 2024 and continuing to grow in 2025. Gross profitability improved materially, with gross profit rising faster than revenue and operating losses narrowing year over year.
What are the risks of investing in BHST?
Claude: Complete absence of revenue and profitability metrics. No balance sheet data available indicating non-reporting status or financial distress. ChatGPT: The company remains unprofitable with persistent net losses and negative operating cash flow. SEC filings include a going-concern warning and management states the business still depends on fundraising to finance operations.
What is BHST's revenue and growth?
Bioharvest Sciences Inc.. reported revenue of N/A.
Does BHST pay dividends?
Bioharvest Sciences Inc.. does not currently pay dividends.
Where can I find BHST SEC filings?
Official SEC filings for Bioharvest Sciences Inc.. (CIK: 0001723464) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BHST's EPS?
Bioharvest Sciences Inc.. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BHST a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Bioharvest Sciences Inc.. has a SELL rating with 84% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BHST stock overvalued or undervalued?
Valuation metrics for BHST: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy BHST stock in 2026?
Our dual AI analysis gives Bioharvest Sciences Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BHST's free cash flow?
Bioharvest Sciences Inc..'s operating cash flow is N/A, with capital expenditures of N/A.
How does BHST compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).